NCT00458523View on ClinicalTrials.gov

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2006

Study Completion Date

February 29, 2008

Conditions
Leukemia
Interventions
BIOLOGICAL

alemtuzumab

GENETIC

fluorescence in situ hybridization

GENETIC

mutation analysis

OTHER

flow cytometry

Trial Locations (2)

CT1 3NG

Kent and Canterbury Hospital, Canterbury

LS1 3EX

Leeds General Infirmary, Leeds

All Listed Sponsors
lead

Leeds Cancer Centre at St. James's University Hospital

OTHER

NCT00458523 - Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission | Biotech Hunter | Biotech Hunter